Influence of Cardiometabolic Risk Factors on Platelet Function
Abstract
:1. Introduction
2. Definition of Metabolic Syndrome
3. Platelets in Hemostasis and Thrombosis
4. Platelet Function Assays
5. Platelet Alterations in Central Obesity
6. In Vivo Markers of Platelet Activation in Obesity
6.1. Mean Platelet Volume
6.2. Arachidonic Acid Metabolites
6.3. Soluble P-Selectin
6.4. CD40 Ligand
6.5. Platelet-Derived Microparticles (PMPs)
7. Contribution of Insulin Resistance on Platelet Dysfunction
8. Type 2 Diabetes Mellitus and Alterations of Platelet Function
8.1. Hyperglycemia
8.2. Oxidative Stress
8.3. Shear Stress
9. Role of Dyslipidemia in the Impaired Platelet Reactivity
10. Hypertension and Platelets
11. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Mendis, S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Prog. Cardiovasc. Dis. 2010, 53, 10–14. [Google Scholar] [CrossRef] [PubMed]
- Lakka, H.-M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288, 2709–2716. [Google Scholar] [CrossRef] [PubMed]
- Mente, A.; Yusuf, S.; Islam, S.; McQueen, M.J.; Tanomsup, S.; Onen, C.L.; Rangarajan, S.; Gerstein, H.C.; Anand, S.S. INTERHEART Investigators Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J. Am. Coll. Cardiol. 2010, 55, 2390–2398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Novo, S.; Peritore, A.; Guarneri, F.P.; Corrado, E.; Macaione, F.; Evola, S.; Novo, G. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis 2012, 223, 468–472. [Google Scholar] [CrossRef] [PubMed]
- Towfighi, A.; Ovbiagele, B. Metabolic syndrome and stroke. Curr. Diabetes Rep. 2008, 8, 37–41. [Google Scholar] [CrossRef] [PubMed]
- Goossens, G.H. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. Obes. Facts 2017, 10, 207–215. [Google Scholar] [CrossRef]
- Grundy, S.M. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002, 105, 2696–2698. [Google Scholar] [CrossRef] [Green Version]
- McGill, H.C.; McMahan, C.A.; Herderick, E.E.; Zieske, A.W.; Malcom, G.T.; Tracy, R.E.; Strong, J.P. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002, 105, 2712–2718. [Google Scholar] [CrossRef]
- Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444, 875–880. [Google Scholar] [CrossRef]
- Després, J.-P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 2006, 444, 881–887. [Google Scholar] [CrossRef]
- Alberti, K.G.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15, 539–553. [Google Scholar] [CrossRef]
- Russo, I. The prothrombotic tendency in metabolic syndrome: Focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. Scientifica 2012, 2012, 525374. [Google Scholar] [CrossRef] [PubMed]
- Ervin, R.B. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl. Health Stat. Rep. 2009, 5, 1–7. [Google Scholar]
- Ford, E.S.; Giles, W.H.; Mokdad, A.H. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004, 27, 2444–2449. [Google Scholar] [CrossRef] [Green Version]
- Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356–359. [Google Scholar] [CrossRef]
- Meigs, J.B. Epidemiology of the metabolic syndrome, 2002. Am. J. Manag. Care 2002, 8, S283–S292. [Google Scholar]
- Jacobson, T.A.; Case, C.C.; Roberts, S.; Buckley, A.; Murtaugh, K.M.; Sung, J.C.Y.; Gause, D.; Varas, C.; Ballantyne, C.M. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes. Metab. 2004, 6, 353–362. [Google Scholar] [CrossRef]
- Grundy, S.M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 629–636. [Google Scholar] [CrossRef] [Green Version]
- Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C.; et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112, 2735–2752. [Google Scholar] [CrossRef] [Green Version]
- Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith, S.C.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640–1645. [Google Scholar]
- Perrone-Filardi, P.; Paolillo, S.; Costanzo, P.; Savarese, G.; Trimarco, B.; Bonow, R.O. The role of metabolic syndrome in heart failure. Eur. Heart J. 2015, 36, 2630–2634. [Google Scholar] [CrossRef] [PubMed]
- Karnchanasorn, R.; Ou, H.-Y.; Chuang, L.-M.; Chiu, K.C. Insulin resistance is not necessarily an essential element of metabolic syndrome. Endocrine 2013, 43, 92–99. [Google Scholar] [CrossRef] [PubMed]
- Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2005, 365, 1415–1428. [Google Scholar] [CrossRef]
- Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome. Med. Inflamm. 2010, 2010, 289645. [Google Scholar] [CrossRef]
- Ford, E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005, 28, 1769–1778. [Google Scholar] [CrossRef] [Green Version]
- Sullivan, P.W.; Ghushchyan, V.; Wyatt, H.R.; Wu, E.Q.; Hill, J.O. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity 2007, 15, 511–521. [Google Scholar] [CrossRef] [Green Version]
- Rivera, J.; Lozano, M.L.; Navarro-Núñez, L.; Vicente, V. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009, 94, 700–711. [Google Scholar] [CrossRef]
- Heijnen, H.; van der Sluijs, P. Platelet secretory behaviour: As diverse as the granules … or not? J. Thromb. Haemost. 2015, 13, 2141–2151. [Google Scholar] [CrossRef]
- Davì, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357, 2482–2494. [Google Scholar] [CrossRef]
- Ruggeri, Z.M. Platelets in atherothrombosis. Nat. Med. 2002, 8, 1227–1234. [Google Scholar] [CrossRef]
- Bakogiannis, C.; Sachse, M.; Stamatelopoulos, K.; Stellos, K. Platelet-derived chemokines in inflammation and atherosclerosis. Cytokine 2019, 122, 154157. [Google Scholar] [CrossRef] [PubMed]
- Silva, M.; Videira, P.A.; Sackstein, R. E-Selectin Ligands in the Human Mononuclear Phagocyte System: Implications for Infection, Inflammation, and Immunotherapy. Front. Immunol. 2017, 8, 1878. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holthenrich, A.; Gerke, V. Regulation of von-Willebrand Factor Secretion from Endothelial Cells by the Annexin A2-S100A10 Complex. Int. J. Mol. Sci. 2018, 19, 1572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koupenova, M.; Clancy, L.; Corkrey, H.A.; Freedman, J.E. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. Circ. Res. 2018, 122, 337–351. [Google Scholar] [CrossRef]
- Gryglewski, R.J.; Botting, R.M.; Vane, J.R. Mediators produced by the endothelial cell. Hypertension 1988, 12, 530–548. [Google Scholar] [CrossRef] [Green Version]
- Harrison, P.; Mackie, I.; Mumford, A.; Briggs, C.; Liesner, R.; Winter, M.; Machin, S. British Committee for Standards in Haematology Guidelines for the laboratory investigation of heritable disorders of platelet function. Br. J. Haematol. 2011, 155, 30–44. [Google Scholar] [CrossRef]
- Hayward, C.P.M.; Moffat, K.A.; Raby, A.; Israels, S.; Plumhoff, E.; Flynn, G.; Zehnder, J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. Am. J. Clin. Pathol. 2010, 134, 955–963. [Google Scholar] [CrossRef] [Green Version]
- Cattaneo, M.; Cerletti, C.; Harrison, P.; Hayward, C.P.M.; Kenny, D.; Nugent, D.; Nurden, P.; Rao, A.K.; Schmaier, A.H.; Watson, S.P.; et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J. Thromb. Haemost. 2013. [Google Scholar] [CrossRef]
- Mackie, I.J.; Jones, R.; Machin, S.J. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J. Clin. Pathol. 1984, 37, 874–878. [Google Scholar] [CrossRef] [Green Version]
- Furman, M.I.; Barnard, M.R.; Krueger, L.A.; Fox, M.L.; Shilale, E.A.; Lessard, D.M.; Marchese, P.; Frelinger, A.L.; Goldberg, R.J.; Michelson, A.D. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J. Am. Coll. Cardiol. 2001, 38, 1002–1006. [Google Scholar] [CrossRef] [Green Version]
- Barnard, M.R.; Linden, M.D.; Frelinger, A.L.; Li, Y.; Fox, M.L.; Furman, M.I.; Michelson, A.D. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J. Thromb. Haemost. 2005, 3, 2563–2570. [Google Scholar] [CrossRef] [PubMed]
- Robert, S.; Lacroix, R.; Poncelet, P.; Harhouri, K.; Bouriche, T.; Judicone, C.; Wischhusen, J.; Arnaud, L.; Dignat-George, F. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles-Brief report. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1054–1058. [Google Scholar] [CrossRef] [PubMed]
- De Cuyper, I.M.; Meinders, M.; van de Vijver, E.; de Korte, D.; Porcelijn, L.; de Haas, M.; Eble, J.A.; Seeger, K.; Rutella, S.; Pagliara, D.; et al. A novel flow cytometry-based platelet aggregation assay. Blood 2013, 121, e70–e80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pakala, R.; Waksman, R. Currently available methods for platelet function analysis: Advantages and disadvantages. Cardiovasc. Revas. Med. 2011, 12, 312–322. [Google Scholar] [CrossRef]
- Kehrel, B.E.; Brodde, M.F. State of the art in platelet function testing. Transfus. Med. Hemother. 2013, 40, 73–86. [Google Scholar] [CrossRef]
- Fontana, P.; Zufferey, A.; Daali, Y.; Reny, J.-L. Antiplatelet therapy: Targeting the TxA2 pathway. J. Cardiovasc. Transl. Res. 2014, 7, 29–38. [Google Scholar] [CrossRef]
- Csige, I.; Ujvárosy, D.; Szabó, Z.; Lőrincz, I.; Paragh, G.; Harangi, M.; Somodi, S. The Impact of Obesity on the Cardiovascular System. J. Diabetes Res. 2018, 2018, 3407306. [Google Scholar] [CrossRef] [Green Version]
- Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med. 2017, 377, 13–27. [Google Scholar]
- Tchernof, A.; Després, J.-P. Pathophysiology of human visceral obesity: An update. Physiol. Rev. 2013, 93, 359–404. [Google Scholar] [CrossRef]
- Kakafika, A.I.; Liberopoulos, E.N.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr. Vasc. Pharmacol. 2006, 4, 175–183. [Google Scholar] [CrossRef]
- Ritchie, S.A.; Connell, J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 319–326. [Google Scholar] [CrossRef] [PubMed]
- Mertens, I.; Van Gaal, L.F. Obesity, haemostasis and the fibrinolytic system. Obes. Rev. 2002, 3, 85–101. [Google Scholar] [CrossRef] [PubMed]
- Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis. 2009, 19, 440–449. [Google Scholar] [CrossRef] [PubMed]
- Beavers, C.J.; Heron, P.; Smyth, S.S.; Bain, J.A.; Macaulay, T.E. Obesity and Antiplatelets-Does One Size Fit All? Thromb. Res. 2015, 136, 712–716. [Google Scholar] [CrossRef]
- Barrachina, M.N.; Sueiro, A.M.; Izquierdo, I.; Hermida-Nogueira, L.; Guitián, E.; Casanueva, F.F.; Farndale, R.W.; Moroi, M.; Jung, S.M.; Pardo, M.; et al. GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: Elucidating potential anti-atherothrombotic targets in obesity. Atherosclerosis 2019, 281, 62–70. [Google Scholar] [CrossRef] [Green Version]
- Anfossi, G.; Russo, I.; Doronzo, G.; Pomero, A.; Trovati, M. Adipocytokines in atherothrombosis: Focus on platelets and vascular smooth muscle cells. Med. Inflamm. 2010, 2010, 174341. [Google Scholar] [CrossRef] [Green Version]
- Santilli, F.; Vazzana, N.; Liani, R.; Guagnano, M.T.; Davì, G. Platelet activation in obesity and metabolic syndrome. Obes. Rev. 2012, 13, 27–42. [Google Scholar] [CrossRef]
- Anfossi, G.; Russo, I.; Trovati, M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr. Diabetes Rev. 2006, 2, 409–430. [Google Scholar]
- Anfossi, G.; Russo, I.; Massucco, P.; Mattiello, L.; Doronzo, G.; De Salve, A.; Trovati, M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: Possible role in platelet hyperactivation in obesity. Eur. J. Clin. Investig. 2004, 34, 482–489. [Google Scholar] [CrossRef]
- Russo, I.; Del Mese, P.; Doronzo, G.; De Salve, A.; Secchi, M.; Trovati, M.; Anfossi, G. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin. Chem. 2007, 53, 1053–1060. [Google Scholar] [CrossRef] [Green Version]
- Russo, I.; Traversa, M.; Bonomo, K.; De Salve, A.; Mattiello, L.; Del Mese, P.; Doronzo, G.; Cavalot, F.; Trovati, M.; Anfossi, G. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity 2010, 18, 788–797. [Google Scholar] [CrossRef] [PubMed]
- Bodary, P.F.; Westrick, R.J.; Wickenheiser, K.J.; Shen, Y.; Eitzman, D.T. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 2002, 287, 1706–1709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vilahur, G.; Ben-Aicha, S.; Badimon, L. New insights into the role of adipose tissue in thrombosis. Cardiovasc. Res. 2017, 113, 1046–1054. [Google Scholar] [CrossRef] [PubMed]
- Klöting, N.; Blüher, M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev. Endocr. Metab. Disord. 2014, 15, 277–287. [Google Scholar] [CrossRef] [PubMed]
- Elbatarny, H.S.; Netherton, S.J.; Ovens, J.D.; Ferguson, A.V.; Maurice, D.H. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: Implication in obesity-associated cardiovascular diseases. Eur. J. Pharmacol. 2007, 558, 7–13. [Google Scholar] [CrossRef]
- Kato, H.; Kashiwagi, H.; Shiraga, M.; Tadokoro, S.; Kamae, T.; Ujiie, H.; Honda, S.; Miyata, S.; Ijiri, Y.; Yamamoto, J.; et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 224–230. [Google Scholar] [CrossRef] [Green Version]
- Golia, E.; Limongelli, G.; Natale, F.; Fimiani, F.; Maddaloni, V.; Russo, P.E.; Riegler, L.; Bianchi, R.; Crisci, M.; Palma, G.D.; et al. Adipose tissue and vascular inflammation in coronary artery disease. World J. Cardiol. 2014, 6, 539–554. [Google Scholar] [CrossRef]
- Abdel-Moneim, A.; Mahmoud, B.; Sultan, E.A.; Mahmoud, R. Relationship of leukocytes, platelet indices and adipocytokines in metabolic syndrome patients. Diabetes Metab. Syndr. 2019, 13, 874–880. [Google Scholar] [CrossRef]
- Yetkin, E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb. Haemost. 2008, 100, 3–4. [Google Scholar] [CrossRef] [Green Version]
- Coban, E.; Ozdogan, M.; Yazicioglu, G.; Akcit, F. The mean platelet volume in patients with obesity. Int. J. Clin. Pract. 2005, 59, 981–982. [Google Scholar] [CrossRef]
- Pinto, R.V.L.; Rodrigues, G.; Simões, R.L.; Porto, L.C. Analysis of Post-Sample Collection EDTA Effects on Mean Platelet Volume Values in Relation to Overweight and Obese Patient Status. Acta Haematol. 2019, 142, 149–153. [Google Scholar] [CrossRef] [PubMed]
- Montilla, M.; Santi, M.J.; Carrozas, M.A.; Ruiz, F.A. Biomarkers of the prothrombotic state in abdominal obesity. Nutr. Hosp. 2014, 31, 1059–1066. [Google Scholar] [PubMed]
- Raoux, L.; Moszkowicz, D.; Vychnevskaia, K.; Poghosyan, T.; Beauchet, A.; Clauser, S.; Bretault, M.; Czernichow, S.; Carette, C.; Bouillot, J.-L. Effect of Bariatric Surgery-Induced Weight Loss on Platelet Count and Mean Platelet Volume: A 12-Month Follow-Up Study. Obes. Surg. 2017, 27, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Smyth, E.M. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin. Lipidol. 2010, 5, 209–219. [Google Scholar] [CrossRef] [Green Version]
- Maclouf, J.; Folco, G.; Patrono, C. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb. Haemost. 1998, 79, 691–705. [Google Scholar]
- Simeone, P.; Boccatonda, A.; Liani, R.; Santilli, F. Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. Ageing Res. Rev. 2018, 48, 51–78. [Google Scholar] [CrossRef]
- Graziani, F.; Biasucci, L.M.; Cialdella, P.; Liuzzo, G.; Giubilato, S.; Della Bona, R.; Pulcinelli, F.M.; Iaconelli, A.; Mingrone, G.; Crea, F. Thromboxane production in morbidly obese subjects. Am. J. Cardiol. 2011, 107, 1656–1661. [Google Scholar] [CrossRef]
- Vincent, H.K.; Innes, K.E.; Vincent, K.R. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes. Metab. 2007, 9, 813–839. [Google Scholar] [CrossRef]
- Horng, T.; Hotamisligil, G.S. Linking the inflammasome to obesity-related disease. Nat. Med. 2011, 17, 164–165. [Google Scholar] [CrossRef]
- Choi, A.M.K.; Nakahira, K. Dampening insulin signaling by an NLRP3 “meta-flammasome”. Nat. Immunol. 2011, 12, 379–380. [Google Scholar] [CrossRef]
- Audoly, L.P.; Rocca, B.; Fabre, J.E.; Koller, B.H.; Thomas, D.; Loeb, A.L.; Coffman, T.M.; FitzGerald, G.A. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000, 101, 2833–2840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- André, P.; Hartwell, D.; Hrachovinová, I.; Saffaripour, S.; Wagner, D.D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc. Natl. Acad. Sci. USA 2000, 97, 13835–13840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamburger, S.A.; McEver, R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990, 75, 550–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Patel, M.S.; Miranda-Nieves, D.; Chen, J.; Haller, C.A.; Chaikof, E.L. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl. Res. 2017, 183, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Evangelista, V.; Manarini, S.; Coller, B.S.; Smyth, S.S. Role of P-selectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion. J. Thromb. Haemost. 2003, 1, 1048–1054. [Google Scholar] [CrossRef] [Green Version]
- Da Costa Martins, P.; van den Berk, N.; Ulfman, L.H.; Koenderman, L.; Hordijk, P.L.; Zwaginga, J.J. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 193–199. [Google Scholar] [CrossRef] [Green Version]
- Kim, K.H.; Barazia, A.; Cho, J. Real-time imaging of heterotypic platelet-neutrophil interactions on the activated endothelium during vascular inflammation and thrombus Formation in live mice. J. Vis. Exp. 2013. [Google Scholar] [CrossRef] [Green Version]
- Sreeramkumar, V.; Adrover, J.M.; Ballesteros, I.; Cuartero, M.I.; Rossaint, J.; Bilbao, I.; Nácher, M.; Pitaval, C.; Radovanovic, I.; Fukui, Y.; et al. Neutrophils scan for activated platelets to initiate inflammation. Science 2014, 346, 1234–1238. [Google Scholar] [CrossRef] [Green Version]
- Bielinski, S.J.; Berardi, C.; Decker, P.A.; Kirsch, P.S.; Larson, N.B.; Pankow, J.S.; Sale, M.; de Andrade, M.; Sicotte, H.; Tang, W.; et al. P-selectin and subclinical and clinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015, 240, 3–9. [Google Scholar] [CrossRef] [Green Version]
- De Pergola, G.; Pannacciulli, N.; Coviello, M.; Scarangella, A.; Di Roma, P.; Caringella, M.; Venneri, M.T.; Quaranta, M.; Giorgino, R. sP-selectin plasma levels in obesity: Association with insulin resistance and related metabolic and prothrombotic factors. Nutr. Metab. Cardiovasc. Dis. 2008, 18, 227–232. [Google Scholar] [CrossRef]
- André, P.; Nannizzi-Alaimo, L.; Prasad, S.K.; Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. Circulation 2002, 106, 896–899. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Henn, V.; Slupsky, J.R.; Gräfe, M.; Anagnostopoulos, I.; Förster, R.; Müller-Berghaus, G.; Kroczek, R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391, 591–594. [Google Scholar] [CrossRef] [PubMed]
- Vishnevetsky, D.; Kiyanista, V.A.; Gandhi, P.J. CD40 ligand: A novel target in the fight against cardiovascular disease. Ann. Pharmacother. 2004, 38, 1500–1508. [Google Scholar] [CrossRef] [PubMed]
- Poggi, M.; Engel, D.; Christ, A.; Beckers, L.; Wijnands, E.; Boon, L.; Driessen, A.; Cleutjens, J.; Weber, C.; Gerdes, N.; et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2251–2260. [Google Scholar] [CrossRef] [Green Version]
- Chakrabarti, S.; Rizvi, M.; Pathak, D.; Kirber, M.T.; Freedman, J.E. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. Immunol. Lett. 2009, 122, 170–184. [Google Scholar] [CrossRef]
- Jeon, H.J.; Choi, J.-H.; Jung, I.-H.; Park, J.-G.; Lee, M.-R.; Lee, M.-N.; Kim, B.; Yoo, J.-Y.; Jeong, S.-J.; Kim, D.-Y.; et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation 2010, 121, 1124–1133. [Google Scholar] [CrossRef] [Green Version]
- Nomura, S.; Shouzu, A.; Omoto, S.; Inami, N.; Shimazu, T.; Satoh, D.; Kajiura, T.; Yamada, K.; Urase, F.; Maeda, Y.; et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. Blood Coagul. Fibrinolysis 2009, 20, 440–447. [Google Scholar] [CrossRef]
- Aggarwal, A.; Blum, A.; Schneider, D.J.; Sobel, B.E.; Dauerman, H.L. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron. Artery Dis. 2004, 15, 471–475. [Google Scholar] [CrossRef]
- Cipollone, F.; Chiarelli, F.; Davì, G.; Ferri, C.; Desideri, G.; Fazia, M.; Iezzi, A.; Santilli, F.; Pini, B.; Cuccurullo, C.; et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: Effect of improved metabolic control. Diabetologia 2005, 48, 1216–1224. [Google Scholar] [CrossRef] [Green Version]
- Ueland, T.; Aukrust, P.; Yndestad, A.; Otterdal, K.; Frøland, S.S.; Dickstein, K.; Kjekshus, J.; Gullestad, L.; Damås, J.K. Soluble CD40 ligand in acute and chronic heart failure. Eur. Heart J. 2005, 26, 1101–1107. [Google Scholar] [CrossRef] [Green Version]
- Oviedo-Orta, E.; Bermudez-Fajardo, A.; Karanam, S.; Benbow, U.; Newby, A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. Immunology 2008, 124, 42–50. [Google Scholar] [CrossRef] [PubMed]
- Jiang, R.-H.; Xu, X.-Q.; Wu, C.-J.; Lu, S.-S.; Zu, Q.-Q.; Zhao, L.-B.; Liu, S.; Shi, H.-B. The CD40/CD40L system regulates rat cerebral microvasculature after focal ischemia/reperfusion via the mTOR/S6K signaling pathway. Neurol. Res. 2018, 40, 717–723. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dovizio, M.; Bruno, A.; Contursi, A.; Grande, R.; Patrignani, P. Platelets and extracellular vesicles in cancer: Diagnostic and therapeutic implications. Cancer Metastasis Rev. 2018, 37, 455–467. [Google Scholar] [CrossRef] [PubMed]
- George, J.N.; Thoi, L.L.; McManus, L.M.; Reimann, T.A. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982, 60, 834–840. [Google Scholar] [CrossRef] [Green Version]
- Zahran, A.M.; Sayed, S.K.; Abd El Hafeez, H.A.; Khalifa, W.A.; Mohamed, N.A.; Hetta, H.F. Circulating microparticle subpopulation in metabolic syndrome: Relation to oxidative stress and coagulation markers. Diabetes Metab. Syndr. Obes. 2019, 12, 485–493. [Google Scholar] [CrossRef] [Green Version]
- Murakami, T.; Horigome, H.; Tanaka, K.; Nakata, Y.; Ohkawara, K.; Katayama, Y.; Matsui, A. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb. Res. 2007, 119, 45–53. [Google Scholar] [CrossRef]
- Grande, R.; Dovizio, M.; Marcone, S.; Szklanna, P.B.; Bruno, A.; Ebhardt, H.A.; Cassidy, H.; Ní Áinle, F.; Caprodossi, A.; Lanuti, P.; et al. Platelet-Derived Microparticles from Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk with Cancer and Endothelial Cells. Front. Pharmacol. 2019, 10, 7. [Google Scholar] [CrossRef] [Green Version]
- Belfiore, A.; Frasca, F.; Pandini, G.; Sciacca, L.; Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 2009, 30, 586–623. [Google Scholar] [CrossRef] [Green Version]
- White, M.F.; Kahn, C.R. The insulin signaling system. J. Biol. Chem. 1994, 269, 1–4. [Google Scholar]
- Taniguchi, C.M.; Emanuelli, B.; Kahn, C.R. Critical nodes in signalling pathways: Insights into insulin action. Nat. Rev. Mol. Cell Biol. 2006, 7, 85–96. [Google Scholar] [CrossRef]
- Reaven, G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2003, 88, 2399–2403. [Google Scholar] [CrossRef] [PubMed]
- Baron, A.D. Insulin resistance and vascular function. J. Diabetes Complicat. 2002, 16, 92–102. [Google Scholar] [CrossRef]
- Muniyappa, R.; Quon, M.J. Insulin action and insulin resistance in vascular endothelium. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10, 523–530. [Google Scholar] [CrossRef] [PubMed]
- Anfossi, G.; Russo, I.; Doronzo, G.; Trovati, M. Contribution of insulin resistance to vascular dysfunction. Arch. Physiol. Biochem. 2009, 115, 199–217. [Google Scholar] [CrossRef]
- Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111, 1448–1454. [Google Scholar] [CrossRef] [Green Version]
- Falcon, C.; Pfliegler, G.; Deckmyn, H.; Vermylen, J. The platelet insulin receptor: Detection, partial characterization, and search for a function. Biochem. Biophys. Res. Commun. 1988, 157, 1190–1196. [Google Scholar] [CrossRef]
- Russo, I.; Massucco, P.; Mattiello, L.; Cavalot, F.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb. Res. 2002, 107, 31–37. [Google Scholar] [CrossRef]
- Russo, I.; Massucco, P.; Mattiello, L.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. Thromb. Res. 2003, 109, 323–327. [Google Scholar] [CrossRef]
- Westerbacka, J.; Yki-Järvinen, H.; Turpeinen, A.; Rissanen, A.; Vehkavaara, S.; Syrjälä, M.; Lassila, R. Inhibition of platelet-collagen interaction: An in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 167–172. [Google Scholar] [CrossRef] [Green Version]
- Mayfield, R.K.; Halushka, P.V.; Wohltmann, H.J.; Lopes-Virella, M.; Chambers, J.K.; Loadholt, C.B.; Colwell, J.A. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. Diabetes 1985, 34, 1127–1133. [Google Scholar] [CrossRef]
- Trovati, M.; Anfossi, G.; Massucco, P.; Mattiello, L.; Costamagna, C.; Piretto, V.; Mularoni, E.; Cavalot, F.; Bosia, A.; Ghigo, D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes 1997, 46, 742–749. [Google Scholar] [CrossRef] [PubMed]
- Gerrits, A.J.; Gitz, E.; Koekman, C.A.; Visseren, F.L.; van Haeften, T.W.; Akkerman, J.W.N. Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. Haematologica 2012, 97, 1149–1157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kawahara, Y.; Yamanishi, J.; Fukuzaki, H. Inhibitory action of guanosine 3’,5’-monophosphate on thrombin-induced calcium mobilization in human platelets. Thromb. Res. 1984, 33, 203–209. [Google Scholar] [CrossRef]
- Resnick, L.M. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: A unifying theme. J. Am. Soc. Nephrol. 1992, 3, S78–S85. [Google Scholar]
- Anfossi, G.; Mularoni, E.M.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Cavalot, F.; Trovati, M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998, 21, 121–126. [Google Scholar] [CrossRef]
- Davì, G.; Guagnano, M.T.; Ciabattoni, G.; Basili, S.; Falco, A.; Marinopiccoli, M.; Nutini, M.; Sensi, S.; Patrono, C. Platelet activation in obese women: Role of inflammation and oxidant stress. JAMA 2002, 288, 2008–2014. [Google Scholar] [CrossRef] [Green Version]
- Simeone, P.; Liani, R.; Tripaldi, R.; Di Castelnuovo, A.; Guagnano, M.T.; Tartaro, A.; Bonadonna, R.C.; Federico, V.; Cipollone, F.; Consoli, A.; et al. Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. Nutrients 2018, 10, 1872. [Google Scholar] [CrossRef] [Green Version]
- Cameron-Vendrig, A.; Reheman, A.; Siraj, M.A.; Xu, X.R.; Wang, Y.; Lei, X.; Afroze, T.; Shikatani, E.; El-Mounayri, O.; Noyan, H.; et al. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes 2016, 65, 1714–1723. [Google Scholar] [CrossRef] [Green Version]
- Barale, C.; Buracco, S.; Cavalot, F.; Frascaroli, C.; Guerrasio, A.; Russo, I. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb. Haemost. 2017, 117, 1115–1128. [Google Scholar] [CrossRef] [Green Version]
- Matsuno, H.; Tokuda, H.; Ishisaki, A.; Zhou, Y.; Kitajima, Y.; Kozawa, O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. J. Clin. Endocrinol. Metab. 2005, 90, 920–927. [Google Scholar] [CrossRef] [Green Version]
- Watala, C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr. Pharm. Des. 2005, 11, 2331–2365. [Google Scholar] [CrossRef] [PubMed]
- Braunwald, E.; Angiolillo, D.; Bates, E.; Berger, P.B.; Bhatt, D.; Cannon, C.P.; Furman, M.I.; Gurbel, P.; Michelson, A.D.; Peterson, E.; et al. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin. Cardiol. 2008, 31, I21–I27. [Google Scholar] [CrossRef] [PubMed]
- Santilli, F.; Marchisio, M.; Lanuti, P.; Boccatonda, A.; Miscia, S.; Davì, G. Microparticles as new markers of cardiovascular risk in diabetes and beyond. Thromb. Haemost. 2016, 116, 220–234. [Google Scholar] [CrossRef] [PubMed]
- Santilli, F.; Simeone, P.; Liani, R.; Davì, G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat. 2015, 120, 28–39. [Google Scholar] [CrossRef]
- Aryangat, A.V.; Gerich, J.E. Type 2 diabetes: Postprandial hyperglycemia and increased cardiovascular risk. Vasc. Health Risk Manag. 2010, 6, 145–155. [Google Scholar] [PubMed] [Green Version]
- Sottero, B.; Gargiulo, S.; Russo, I.; Barale, C.; Poli, G.; Cavalot, F. Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. Med. Res. Rev. 2015, 35, 968–1031. [Google Scholar] [CrossRef] [PubMed]
- Davì, G.; Catalano, I.; Averna, M.; Notarbartolo, A.; Strano, A.; Ciabattoni, G.; Patrono, C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N. Engl. J. Med. 1990, 322, 1769–1774. [Google Scholar] [CrossRef]
- Temelkova-Kurktschiev, T.S.; Koehler, C.; Henkel, E.; Leonhardt, W.; Fuecker, K.; Hanefeld, M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000, 23, 1830–1834. [Google Scholar] [CrossRef] [Green Version]
- Donahue, R.P.; Abbott, R.D.; Reed, D.M.; Yano, K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987, 36, 689–692. [Google Scholar] [CrossRef]
- Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999, 354, 617–621.
- Gresele, P.; Guglielmini, G.; De Angelis, M.; Ciferri, S.; Ciofetta, M.; Falcinelli, E.; Lalli, C.; Ciabattoni, G.; Davì, G.; Bolli, G.B. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J. Am. Coll. Cardiol. 2003, 41, 1013–1020. [Google Scholar] [CrossRef] [Green Version]
- Barstad, R.M.; Orvim, U.; Hamers, M.J.; Tjønnfjord, G.E.; Brosstad, F.R.; Sakariassen, K.S. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb. Haemost. 1996, 75, 827–832. [Google Scholar] [CrossRef] [PubMed]
- Folts, J.D.; Schafer, A.I.; Loscalzo, J.; Willerson, J.T.; Muller, J.E. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. J. Am. Coll. Cardiol. 1999, 33, 295–303. [Google Scholar] [CrossRef] [Green Version]
- Russo, I.; Viretto, M.; Barale, C.; Mattiello, L.; Doronzo, G.; Pagliarino, A.; Cavalot, F.; Trovati, M.; Anfossi, G. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012, 61, 2913–2921. [Google Scholar] [CrossRef] [Green Version]
- Finamore, F.; Reny, J.-L.; Malacarne, S.; Fontana, P.; Sanchez, J.-C. A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study. J. Proteomics 2019, 192, 258–266. [Google Scholar] [CrossRef]
- Ferroni, P.; Basili, S.; Falco, A.; Davì, G. Platelet activation in type 2 diabetes mellitus. J. Thromb. Haemost. 2004, 2, 1282–1291. [Google Scholar] [CrossRef]
- Chung, S.S.M.; Ho, E.C.M.; Lam, K.S.L.; Chung, S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 2003, 14, S233–S236. [Google Scholar] [CrossRef] [Green Version]
- Wachowicz, B.; Olas, B.; Zbikowska, H.M.; Buczyński, A. Generation of reactive oxygen species in blood platelets. Platelets 2002, 13, 175–182. [Google Scholar] [CrossRef]
- Tang, W.H.; Stitham, J.; Gleim, S.; Di Febbo, C.; Porreca, E.; Fava, C.; Tacconelli, S.; Capone, M.; Evangelista, V.; Levantesi, G.; et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J. Clin. Investig. 2011, 121, 4462–4476. [Google Scholar] [CrossRef] [Green Version]
- Santilli, F.; Davì, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattoni, G.; Basili, S.; et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2006, 47, 391–397. [Google Scholar] [CrossRef] [Green Version]
- Russo, I.; Penna, C.; Musso, T.; Popara, J.; Alloatti, G.; Cavalot, F.; Pagliaro, P. Platelets, diabetes and myocardial ischemia/reperfusion injury. Cardiovasc. Diabetol. 2017, 16, 71. [Google Scholar] [CrossRef] [PubMed]
- Przyklenk, K.; Maynard, M.; Greiner, D.L.; Whittaker, P. Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid. Redox Signal. 2011, 14, 781–790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Russo, I.; Femminò, S.; Barale, C.; Tullio, F.; Geuna, S.; Cavalot, F.; Pagliaro, P.; Penna, C. Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. Front. Physiol. 2018, 9, 875. [Google Scholar] [CrossRef] [PubMed]
- Tang, W.H.; Stitham, J.; Jin, Y.; Liu, R.; Lee, S.H.; Du, J.; Atteya, G.; Gleim, S.; Spollett, G.; Martin, K.; et al. Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 2014, 129, 1598–1609. [Google Scholar] [CrossRef] [Green Version]
- Thushara, R.M.; Hemshekhar, M.; Basappa; Kemparaju, K.; Rangappa, K.S.; Girish, K.S. Biologicals, platelet apoptosis and human diseases: An outlook. Crit. Rev. Oncol. Hematol. 2015, 93, 149–158. [Google Scholar] [CrossRef]
- Williams, P.C.; Coffey, M.J.; Coles, B.; Sanchez, S.; Morrow, J.D.; Cockcroft, J.R.; Lewis, M.J.; O’Donnell, V.B. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 2005, 106, 2737–2743. [Google Scholar] [CrossRef]
- Worthley, M.I.; Holmes, A.S.; Willoughby, S.R.; Kucia, A.M.; Heresztyn, T.; Stewart, S.; Chirkov, Y.Y.; Zeitz, C.J.; Horowitz, J.D. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J. Am. Coll. Cardiol. 2007, 49, 304–310. [Google Scholar] [CrossRef]
- Watala, C.; Boncer, M.; Golański, J.; Koziołkiewcz, W.; Trojanowski, Z.; Walkowiak, B. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. Eur. J. Haematol. 1998, 61, 319–326. [Google Scholar] [CrossRef]
- Obydennyy, S.I.; Sveshnikova, A.N.; Ataullakhanov, F.I.; Panteleev, M.A. Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. J. Thromb. Haemost. 2016, 14, 1867–1881. [Google Scholar] [CrossRef]
- Pignatelli, P.; Carnevale, R.; Di Santo, S.; Bartimoccia, S.; Sanguigni, V.; Lenti, L.; Finocchi, A.; Mendolicchio, L.; Soresina, A.R.; Plebani, A.; et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 423–434. [Google Scholar] [CrossRef] [Green Version]
- Carnevale, R.; Loffredo, L.; Nocella, C.; Bartimoccia, S.; Sanguigni, V.; Soresina, A.; Plebani, A.; Azzari, C.; Martire, B.; Pignata, C.; et al. Impaired platelet activation in patients with hereditary deficiency of p47phox. Br. J. Haematol. 2018, 180, 454–456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cangemi, R.; Pignatelli, P.; Carnevale, R.; Nigro, C.; Proietti, M.; Angelico, F.; Lauro, D.; Basili, S.; Violi, F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 2012, 61, 1626–1632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lawson, J.A.; Rokach, J.; FitzGerald, G.A. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 1999, 274, 24441–24444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Davì, G.; Ciabattoni, G.; Consoli, A.; Mezzetti, A.; Falco, A.; Santarone, S.; Pennese, E.; Vitacolonna, E.; Bucciarelli, T.; Costantini, F.; et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 1999, 99, 224–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grabowski, E.F.; Jaffe, E.A.; Weksler, B.B. Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J. Lab. Clin. Med. 1985, 105, 36–43. [Google Scholar] [PubMed]
- Schlossmann, J.; Feil, R.; Hofmann, F. Signaling through NO and cGMP-dependent protein kinases. Ann. Med. 2003, 35, 21–27. [Google Scholar] [CrossRef] [PubMed]
- Mazzucato, M.; Santomaso, A.; Canu, P.M.; Ruggeri, Z.; De Marco, L. Flow dynamics and haemostasis. Ann. dell’Istituto Super. Sanità 2007, 43, 130–138. [Google Scholar]
- Westein, E.; Hoefer, T.; Calkin, A.C. Thrombosis in diabetes: A shear flow effect? Clin. Sci. 2017, 131, 1245–1260. [Google Scholar] [CrossRef]
- Choi, H.; Aboulfatova, K.; Pownall, H.J.; Cook, R.; Dong, J. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J. Biol. Chem. 2007, 282, 35604–35611. [Google Scholar] [CrossRef] [Green Version]
- Rehder, D.S.; Borges, C.R. Cysteine sulfenic acid as an intermediate in disulfide bond formation and nonenzymatic protein folding. Biochemistry 2010, 49, 7748–7755. [Google Scholar] [CrossRef] [Green Version]
- Jain, S.K. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J. Biol. Chem. 1989, 264, 21340–21345. [Google Scholar] [PubMed]
- Da, Q.; Teruya, M.; Guchhait, P.; Teruya, J.; Olson, J.S.; Cruz, M.A. Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: Implications for circulatory devices. Blood 2015, 126, 2338–2341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carvalho, A.C.; Colman, R.W.; Lees, R.S. Platelet function in hyperlipoproteinemia. N. Engl. J. Med. 1974, 290, 434–438. [Google Scholar] [CrossRef] [PubMed]
- Pawlowska, Z.; Swiatkowska, M.; Krzeslowska, J.; Pawlicki, L.; Cierniewski, C.S. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis 1993, 103, 13–20. [Google Scholar] [CrossRef]
- Relou, I.A.M.; Hackeng, C.M.; Akkerman, J.-W.N.; Malle, E. Low-density lipoprotein and its effect on human blood platelets. Cell. Mol. Life Sci. 2003, 60, 961–971. [Google Scholar] [CrossRef]
- Ou, H.-C.; Song, T.-Y.; Yeh, Y.-C.; Huang, C.-Y.; Yang, S.-F.; Chiu, T.-H.; Tsai, K.-L.; Chen, K.-L.; Wu, Y.-J.; Tsai, C.-S.; et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. J. Appl. Physiol. 2010, 108, 1745–1756. [Google Scholar] [CrossRef] [Green Version]
- Naseem, K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 2005, 26, 33–65. [Google Scholar] [CrossRef]
- Barale, C.; Frascaroli, C.; Cavalot, F.; Russo, I. Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Thromb. Res. 2019, 180, 74–85. [Google Scholar] [CrossRef]
- Willoughby, S.R.; Stewart, S.; Holmes, A.S.; Chirkov, Y.Y.; Horowitz, J.D. Platelet nitric oxide responsiveness: A novel prognostic marker in acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2661–2666. [Google Scholar] [CrossRef] [Green Version]
- Riba, R.; Nicolaou, A.; Troxler, M.; Homer-Vaniasinkam, S.; Naseem, K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175, 69–75. [Google Scholar] [CrossRef]
- Magwenzi, S.; Woodward, C.; Wraith, K.S.; Aburima, A.; Raslan, Z.; Jones, H.; McNeil, C.; Wheatcroft, S.; Yuldasheva, N.; Febbriao, M.; et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood 2015, 125, 2693–2703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akkerman, J.W.N. From low-density lipoprotein to platelet activation. Int. J. Biochem. Cell Biol. 2008, 40, 2374–2378. [Google Scholar] [CrossRef] [PubMed]
- Barale, C.; Bonomo, K.; Frascaroli, C.; Morotti, A.; Guerrasio, A.; Cavalot, F.; Russo, I. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis. 2019. [Google Scholar] [CrossRef] [PubMed]
- Barale, C.; Frascaroli, C.; Senkeev, R.; Cavalot, F.; Russo, I. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. Biomed. Res. Int. 2018, 2018, 6508709. [Google Scholar] [CrossRef] [Green Version]
- Kanshana, J.S.; Khanna, V.; Singh, V.; Jain, M.; Misra, A.; Kumar, S.; Farooqui, M.; Barthwal, M.K.; Dikshit, M. Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin. J. Cardiovasc. Pharmacol. 2017, 69, 314–325. [Google Scholar] [CrossRef]
- Chu, F.; Wang, M.; Ma, H.; Zhu, J. Simvastatin Modulates Interaction Between Vascular Smooth Muscle Cell/Macrophage and TNF-α-Activated Endothelial Cell. J. Cardiovasc. Pharmacol. 2018, 71, 268–274. [Google Scholar] [CrossRef]
- Diamantis, E.; Kyriakos, G.; Quiles-Sanchez, L.V.; Farmaki, P.; Troupis, T. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. Curr. Cardiol. Rev. 2017, 13, 209–216. [Google Scholar] [CrossRef]
- Kinlay, S.; Selwyn, A.P. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am. J. Cardiol. 2003, 91, 9B–13B. [Google Scholar] [CrossRef]
- Sadowitz, B.; Maier, K.G.; Gahtan, V. Basic science review: Statin therapy—Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc. Endovasc. Surg. 2010, 44, 241–251. [Google Scholar] [CrossRef]
- Sobol, A.B.; Watala, C. The role of platelets in diabetes-related vascular complications. Diabetes Res. Clin. Pract. 2000, 50, 1–16. [Google Scholar] [CrossRef]
- Vinik, A.I.; Erbas, T.; Park, T.S.; Nolan, R.; Pittenger, G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001, 24, 1476–1485. [Google Scholar] [CrossRef] [Green Version]
- Okerson, T.; Chilton, R.J. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc. Ther. 2012, 30, e146–e155. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.-S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117, 2340–2350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seidah, N.G. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr. Pharm. Des. 2013, 19, 3161–3172. [Google Scholar] [CrossRef] [PubMed]
- Camera, M.; Rossetti, L.; Barbieri, S.S.; Zanotti, I.; Canciani, B.; Trabattoni, D.; Ruscica, M.; Tremoli, E.; Ferri, N. PCSK9 as a Positive Modulator of Platelet Activation. J. Am. Coll. Cardiol. 2018, 71, 952–954. [Google Scholar] [CrossRef] [PubMed]
- Navarese, E.P.; Kolodziejczak, M.; Winter, M.-P.; Alimohammadi, A.; Lang, I.M.; Buffon, A.; Lip, G.Y.; Siller-Matula, J.M. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int. J. Cardiol. 2017, 227, 644–649. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Zhu, C.-G.; Guo, Y.-L.; Xu, R.-X.; Zhang, Y.; Sun, J.; Li, J.-J. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. J. Atheroscler. Thromb. 2015, 22, 76–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pastori, D.; Nocella, C.; Farcomeni, A.; Bartimoccia, S.; Santulli, M.; Vasaturo, F.; Carnevale, R.; Menichelli, D.; Violi, F.; Pignatelli, P.; et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients with Atrial Fibrillation. J. Am. Coll. Cardiol. 2017, 70, 1455–1462. [Google Scholar] [CrossRef]
- Harmon, J.T.; Tandon, N.N.; Hoeg, J.M.; Jamieson, G.A. Thrombin binding and response in platelets from patients with dyslipoproteinemias: Increased stimulus-response coupling in type II hyperlipoproteinemia. Blood 1986, 68, 498–505. [Google Scholar] [CrossRef] [Green Version]
- Yamazaki, M.; Uchiyama, S.; Xiong, Y.; Nakano, T.; Nakamura, T.; Iwata, M. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. Thromb. Res. 2005, 115, 211–218. [Google Scholar] [CrossRef]
- Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98, 1352–1364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Calkin, A.C.; Drew, B.G.; Ono, A.; Duffy, S.J.; Gordon, M.V.; Schoenwaelder, S.M.; Sviridov, D.; Cooper, M.E.; Kingwell, B.A.; Jackson, S.P. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009, 120, 2095–2104. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, Y.; Ashraf, M.Z.; Podrez, E.A. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 2010, 116, 1932–1941. [Google Scholar] [CrossRef] [Green Version]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285, 2486–2497.
- Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005, 365, 217–223. [Google Scholar] [CrossRef]
- Diodati, J.G.; Cannon, R.O.; Hussain, N.; Quyyumi, A.A. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. Am. J. Cardiol. 1995, 75, 443–448. [Google Scholar] [CrossRef]
- Cooke, J.P.; Dzau, V.J. Nitric oxide synthase: Role in the genesis of vascular disease. Annu. Rev. Med. 1997, 48, 489–509. [Google Scholar] [CrossRef] [Green Version]
- Nityanand, S.; Pande, I.; Bajpai, V.K.; Singh, L.; Chandra, M.; Singh, B.N. Platelets in essential hypertension. Thromb. Res. 1993, 72, 447–454. [Google Scholar] [CrossRef]
- Torsellini, A.; Becucci, A.; Citi, S.; Cozzolino, F.; Guidi, G.; Lombardi, V.; Vercelli, D.; Veloci, M. Effects of pressure excursions on human platelets. In vitro studies on betathromboglobulin (beta-TG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982, 67, 860–866. [Google Scholar]
- Camilletti, A.; Moretti, N.; Giacchetti, G.; Faloia, E.; Martarelli, D.; Mantero, F.; Mazzanti, L. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am. J. Hypertens. 2001, 14, 382–386. [Google Scholar] [CrossRef]
- Cerecedo, D.; Martínez-Vieyra, I.; Alonso-Rangel, L.; Benítez-Cardoza, C.; Ortega, A. Epithelial sodium channel modulates platelet collagen activation. Eur. J. Cell Biol. 2014, 93, 127–136. [Google Scholar] [CrossRef] [PubMed]
- Galluccio, E.; Cassina, L.; Russo, I.; Gelmini, F.; Setola, E.; Rampoldi, L.; Citterio, L.; Rossodivita, A.; Kamami, M.; Colombo, A.; et al. A novel truncated form of eNOS associates with altered vascular function. Cardiovasc. Res. 2014, 101, 492–502. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lüscher, T.F.; Barton, M. Biology of the endothelium. Clin. Cardiol. 1997, 20, II–3–10. [Google Scholar] [PubMed]
- Taddei, S.; Ghiadoni, L.; Virdis, A.; Versari, D.; Salvetti, A. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. Curr. Pharm. Des. 2003, 9, 2385–2402. [Google Scholar] [CrossRef] [PubMed]
- Russo, I.; Viretto, M.; Doronzo, G.; Barale, C.; Mattiello, L.; Anfossi, G.; Trovati, M. A short-term incubation with high glucose impairs VASP phosphorylation at serine 239 in response to the nitric oxide/cGMP pathway in vascular smooth muscle cells: Role of oxidative stress. Biomed. Res. Int. 2014, 2014, 328959. [Google Scholar] [CrossRef] [PubMed]
- Paolocci, N.; Biondi, R.; Bettini, M.; Lee, C.I.; Berlowitz, C.O.; Rossi, R.; Xia, Y.; Ambrosio, G.; L’Abbate, A.; Kass, D.A.; et al. Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart. J. Mol. Cell. Cardiol. 2001, 33, 671–679. [Google Scholar] [CrossRef]
- Marletta, M.A. Nitric oxide synthase structure and mechanism. J. Biol. Chem. 1993, 268, 12231–12234. [Google Scholar]
- Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002–2012. [Google Scholar]
- Dean, W.L.; Pope, J.E.; Brier, M.E.; Aronoff, G.R. Platelet calcium transport in hypertension. Hypertension 1994, 23, 31–37. [Google Scholar] [CrossRef] [Green Version]
- Möhle, R.; Green, D.; Moore, M.A.; Nachman, R.L.; Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. USA 1997, 94, 663–668. [Google Scholar] [CrossRef] [Green Version]
- Blann, A.D.; Belgore, F.M.; Constans, J.; Conri, C.; Lip, G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am. J. Cardiol. 2001, 87, 1160–1163. [Google Scholar] [CrossRef]
- Tsai, W.-C.; Li, Y.-H.; Huang, Y.-Y.; Lin, C.-C.; Chao, T.-H.; Chen, J.-H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. 2005, 109, 39–43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Belgore, F.M.; Blann, A.D.; Li-Saw-Hee, F.L.; Beevers, D.G.; Lip, G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am. J. Cardiol. 2001, 87, 805–807. [Google Scholar] [CrossRef]
- Ferroni, P.; Martini, F.; D’Alessandro, R.; Magnapera, A.; Raparelli, V.; Scarno, A.; Davì, G.; Basili, S.; Guadagni, F. In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. Clin. Chim. Acta 2008, 388, 33–37. [Google Scholar] [CrossRef]
- Zicha, J.; Kunes, J.; Devynck, M.A. Abnormalities of membrane function and lipid metabolism in hypertension: A review. Am. J. Hypertens. 1999, 12, 315–331. [Google Scholar] [CrossRef]
- Chap, H.J.; Zwaal, R.F.; van Deenen, L.L. Action of highly purified phospholipases on blood platelets. Evidence for an asymmetric distribution of phospholipids in the surface membrane. Biochim. Biophys. Acta 1977, 467, 146–164. [Google Scholar] [CrossRef]
- Bevers, E.M.; Comfurius, P.; Zwaal, R.F. Changes in membrane phospholipid distribution during platelet activation. Biochim. Biophys. Acta 1983, 736, 57–66. [Google Scholar] [CrossRef]
- García-Rubio, D.; Rodríguez-Varela, M.; Martínez-Vieyra, I.; de la Mora, M.B.; Méndez-Méndez, J.V.; Durán-Álvarez, J.C.; Cerecedo, D. Alterations to the contents of plasma membrane structural lipids are associated with structural changes and compartmentalization in platelets in hypertension. Exp. Cell Res. 2019, 385, 111692. [Google Scholar] [CrossRef]
Markers |
---|
Mean Platelet Volume |
Thromboxane B2 |
Prostaglandin F2α |
Soluble P-Selectin |
Soluble CD40L |
Platelet-derived Microparticles |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barale, C.; Russo, I. Influence of Cardiometabolic Risk Factors on Platelet Function. Int. J. Mol. Sci. 2020, 21, 623. https://doi.org/10.3390/ijms21020623
Barale C, Russo I. Influence of Cardiometabolic Risk Factors on Platelet Function. International Journal of Molecular Sciences. 2020; 21(2):623. https://doi.org/10.3390/ijms21020623
Chicago/Turabian StyleBarale, Cristina, and Isabella Russo. 2020. "Influence of Cardiometabolic Risk Factors on Platelet Function" International Journal of Molecular Sciences 21, no. 2: 623. https://doi.org/10.3390/ijms21020623